Pharmaceutical giant Sanofi has announced that its dengue fever vaccine has achieved a 60.8% success rate in large-scale clinical trials.
The trials were conducted in Brazil, Columbia, Mexico, Honduras and Puerto Rico and found that, of the 20,875 children immunized in the study, 42.3% became immune to the disease. Although this a considerably lower success rate than what most vaccines have, Sanofi’s dengue fever vaccine shows that it lessens the severity of dengue fever by close to 90%, making it an effective immunity booster.
Sanofi’s dengue vaccine, Dengvaxia, was approved for use in late 2016 and is now available in several countries including Mexico.
This announcement comes just a few days after the beginnings of what appears to be a dengue fever outbreak in Japan. A total of 47 people in the Tokyo, Japan area have been diagnosed with the disease since August 27. This is the first dengue fever outbreak in the country in nearly 70 years.
Dengue fever is a mosquito-borne disease that causes fever, headache, and muscle and joint pain. It can develop into a serious condition if untreated. Nearly half the world’s population is at risk of contracting the disease, and it affects as many as 100 million people per year.
While no vaccine is currently on the market for dengue fever in the United States, it is available at Passport Health’s Mexico clinics. The CDC does have some preventative measures that can be taken like using mosquito nets or insect repellant in order to avoid infection.
For more information on dengue fever or other tropical diseases, especially if you will be traveling to an affected zone, please contact a Passport Health travel specialist via our website or by calling 1-888-499-PASS (7277).